Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00069862 | Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia | PHASE1 | COMPLETED | 25 | — | — | Sep 1, 2003 | Nov 1, 2005 | Mar 5, 2015 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Deferitrin (GT56-252) | DRUG | - |
| desferoxamine (DFO) | DRUG | - |
Inclusion Criteria: * Beta-thalassemia patients, 18 years of age or older, currently undergoing chronic blood transfusion therapy and iron chelation therapy who weigh more than 40 kg. * No clinically significant findings on physical exam, medical history, or screening laboratories. * Serum ferritin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. | AGIO | 5 | PHASE3 | Mitapivat, AG-348 |
| Bristol-Myers Squibb Company | BMY | 6 | PHASE3 | Luspatercept, ACE-536 |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | CTX001 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | Etavopivat A, Etavopivat B, Etavopivat C |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN7999 |
| ICON Plc | ICLR | 1 | PHASE2 | SP-420 |
| Editas Medicine, Inc. | EDIT | 2 | PHASE1 | EDIT-301 |
| Illumina, Inc. | ILMN | 1 | — | Undisclosed |